Entry of β‐elemene into various phases of clinical trials advocates its significance as a premium candidate likely to gain access to mainstream medicine. Based on the insights gleaned from decades of research, it seems increasingly transparent that β‐elemene has shown significant ability to modulate multiple cell signaling pathways in different cancers. We partition this multicomponent review into how β‐elemene strategically modulates various signal transduction cascades. We have individually summarized regulation of tumor necrosis factor related apoptosis‐inducing ligand, signal transducers and activators of transcription, transforming growth factor/SMAD, NOTCH, and mammalian target of rapamycin pathways by β‐elemene. Last, we will discuss the results of clinical trials of β‐elemene and how effectively we can use these findings to stratify patients who can benefit most from β‐elemene.
Regulation of signaling pathways by β‐elemene in cancer progression and metastasis
M. Qureshi,R. Attar,M. A. Romero,U. Sabitaliyevich,S. B. Nurmurzayevich,O. Ozturk,L. H. Wakim,Xiukun Lin,U. Ozbey,A. Yelekenova,A. Farooqi
Published 2019 in Journal of Cellular Biochemistry
ABSTRACT
PUBLICATION RECORD
- Publication year
2019
- Venue
Journal of Cellular Biochemistry
- Publication date
2019-08-01
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-63 of 63 references · Page 1 of 1
CITED BY
Showing 1-30 of 30 citing papers · Page 1 of 1